Immune checkpoint inhibitors, such as anti-PD1/PDL1 antibodies, have achieved satisfactory results in the treatment of several cancer types, and Hao Zhang et al. showed that the expression of lncRNAs in GBM can be used to assess responsiveness to immune checkpoint therapies 56, 57. Here, CD274 is linked to glioblastoma.